Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolescents and adult patients with Hereditary Angioedema.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Takeda Announces Share Repurchase Plan for 2025
- Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed
- Takeda’s Earnings Call Reveals Mixed Performance, Optimistic Outlook
- Vivek Ramaswamy’s Net Worth – The Youngest Billionaire Republican Presidential Candidate
- TAK Upcoming Earnings Report: What to Expect?